plerixafor has been researched along with Anemia, Sickle Cell in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 8 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akel, S; Fitzhugh, C; Gossett, JM; Hankins, JS; Hsieh, MM; Kang, G; Leonard, A; Panch, S; Poston, L; Sharma, A; Stroncek, D; Tisdale, JF; Uchida, N; Weiss, MJ; West, K; Zheng, Y | 1 |
| Duenas, DM; Johnson, LM; Wilfond, BS | 1 |
| Asmal, M; Bonner, M; Huang, W; Kanter, J; Krishnamurti, L; Kwiatkowski, JL; Mapara, MY; Pierciey, FJ; Ribeil, JA; Shestopalov, I; Thompson, AA; Tisdale, JF; Walters, MC | 1 |
| Agarwal, S; Bakane, A; Kharya, G; Rauthan, A | 1 |
| Fitzhugh, C; Hankins, JS; Hauffe, S; Hsieh, M; Hughes, TE; Leonard, A; Molloy, E; Panch, SR; Sharma, A; Stroncek, D; Taylor, T; Tisdale, JF; Tsai, SQ; Uchida, N; Weiss, MJ; West, K; Wilson, M | 2 |
| Avecilla, ST; Boulad, F; Sadelain, M; Shi, PA; Yazdanbakhsh, K | 1 |
| Boulad, F; Sadelain, M; Shi, PA; Yazdanbakhsh, K; Zhang, J | 1 |
| André-Schmutz, I; Cavazzana, M; Couzin, C; Delville, M; Félix, T; Gabrion, A; Joseph, L; Lagresle-Peyrou, C; Lamhaut, L; Lefrère, F; Magnani, A; Magrin, E; Miccio, A; Plantier, C; Ribeil, JA; Romano, O; Sadek, H; Stanislas, A; Ternaux, B; Tréluyer, JM; Weber, L | 1 |
| Billett, HH; Branch, C; Choi, E; Cui, MH; Mohandas, N; Shi, PA; Yazdanbakhsh, K | 1 |
5 trial(s) available for plerixafor and Anemia, Sickle Cell
| Article | Year |
|---|---|
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
Topics: Adult; Anemia, Sickle Cell; Autografts; Benzylamines; Blood Component Removal; Bone Marrow; Cyclams; Female; Genetic Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged | 2020 |
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Severity of Illness Index | 2021 |
Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease.
Topics: Anemia, Sickle Cell; Antigens, CD34; Benzylamines; Cyclams; Hematocrit; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans | 2021 |
Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.
Topics: Anemia, Sickle Cell; Autografts; Benzylamines; Cyclams; Female; Genetic Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male | 2021 |
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.
Topics: Anemia, Sickle Cell; Anti-HIV Agents; Antigens, CD34; Antisickling Agents; Benzylamines; Blood Transfusion; Case-Control Studies; Cells, Cultured; Cohort Studies; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Hydroxyurea | 2018 |
5 other study(ies) available for plerixafor and Anemia, Sickle Cell
| Article | Year |
|---|---|
Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Benzylamines; Blood Component Removal; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis | 2022 |
Greater Than Minimal Risk, No Direct Benefit - Bridging Drug Trials and Novel Therapy in Pediatric Populations.
Topics: Anemia, Sickle Cell; Benzylamines; Child; Clinical Trials as Topic; Cyclams; Ethics Committees, Research; Heterocyclic Compounds; Humans; Minors; Research Design; Risk Assessment | 2020 |
Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.
Topics: Anemia, Sickle Cell; Benzylamines; Cyclams; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Transplantation Conditioning | 2021 |
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.
Topics: Anemia, Sickle Cell; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Blood Stem Cells; Transplantation, Autologous | 2020 |
No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Benzylamines; Bone Marrow; Cerebrovascular Disorders; Chemokine CXCL12; Cyclams; Disease Models, Animal; Female; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Injections, Subcutaneous; Male; Mice; Mice, Transgenic; Protein Binding; Receptors, CXCR4 | 2016 |